Provider differences in biosimilar uptake in the filgrastim market.
CONCLUSIONS: This study uncovers important associations between provider practice characteristics and biosimilar uptake. Our findings suggest that provider awareness and incentives can be important levers to strengthen US biosimilar market penetration and competition.
PMID: 32436678 [PubMed - in process]
Source: The American Journal of Managed Care - Category: Health Management Authors: Chen AJ, Ribero R, Van Nuys K Tags: Am J Manag Care Source Type: research
More News: Databases & Libraries | Filgrastim | Health Management | Managed Care | Neulasta | Neupogen | Study